QRG Capital Management Inc. Takes $221,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

QRG Capital Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 805 shares of the biopharmaceutical company’s stock, valued at approximately $221,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Alnylam Pharmaceuticals by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock valued at $1,792,542,000 after purchasing an additional 50,366 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after buying an additional 201,784 shares in the last quarter. Capital International Investors boosted its stake in Alnylam Pharmaceuticals by 1.8% during the first quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock valued at $545,674,000 after buying an additional 64,560 shares during the period. Capital Research Global Investors grew its position in Alnylam Pharmaceuticals by 7.3% during the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after buying an additional 214,908 shares in the last quarter. Finally, Bellevue Group AG increased its stake in Alnylam Pharmaceuticals by 3.7% in the 1st quarter. Bellevue Group AG now owns 918,284 shares of the biopharmaceutical company’s stock worth $137,238,000 after acquiring an additional 32,966 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $268.95 on Wednesday. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The firm has a market cap of $34.69 billion, a P/E ratio of -102.65 and a beta of 0.39. The business’s 50 day moving average price is $274.82 and its 200-day moving average price is $233.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same quarter in the prior year, the firm posted $1.15 earnings per share. The company’s revenue for the quarter was down 33.3% on a year-over-year basis. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

Analyst Ratings Changes

ALNY has been the subject of a number of research analyst reports. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday. Scotiabank boosted their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. TD Cowen raised their price objective on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Raymond James upped their target price on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Finally, Bank of America raised their price target on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $294.50.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.